This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Classification codes | C88 (KCD-8 / ICD-10) |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| Synonyms | Waldenström macroglobulinemia (WM), heavy chain disease (HCD), immunoproliferative small intestinal disease (IPSID), alpha heavy chain disease, gamma heavy chain disease (Franklin disease), mu heavy chain disease, malignant immunoproliferative disease |
| Adult onset | Very high (median age at onset of WM about 70 years; heavy chain diseases also mainly in people in their 60s or older) |
Contents
Summary: In 1944, Waldenström described a syndrome characterized by monoclonal IgM proliferation and hyperviscosity, and various subtypes such as heavy chain diseases and immunoproliferative small intestinal disease were subsequently discovered.
Waldenström's Macroglobulinemia (WM) was first introduced in 1944 when the Swedish hematologist Jan G. Waldenström (1906–1996) described two cases characterized by elevated serum viscosity and an abnormal high-molecular-weight protein (later identified as IgM). Waldenström intuitively recognized this disease as a distinct clinical entity separate from multiple myeloma and presented the typical clinical picture characterized by nasal and gum bleeding, lymphadenopathy, and visual disturbance and neurological symptoms due to hyperviscosity.
In the 1960s, heavy chain diseases caused by abnormal clones secreting only immunoglobulin heavy chains began to be reported. In 1964, Franklin described gamma heavy chain disease (γ-HCD, Franklin disease), and subsequently alpha heavy chain disease (α-HCD, immunoproliferative small intestinal disease) and mu heavy chain disease (μ-HCD) were described in turn. Malignant immunoproliferative diseases was adopted in the ICD classification as C88, a conceptual category grouping these various conditions.
Molecular biological understanding of WM advanced dramatically with the discovery of the MYD88 L265P mutation in 2012 (Treon SP et al., N Engl J Med 2012). Identification of MYD88 L265P in more than 90% of WM patients increased diagnostic specificity, and as it became clear that this mutation activates the BTK (Bruton's tyrosine kinase) pathway, BTK inhibitors became established as standard treatment for WM. In 2013, ibrutinib first demonstrated efficacy in WM through a clinical trial, and later zanubrutinib received FDA approval with an improved safety profile compared with ibrutinib in the ASPEN trial (published in NEJM in 2020).
Alpha heavy chain disease (immunoproliferative small intestinal disease, IPSID) was established in 1968 when Seligmann et al. described a proliferation of plasma cells and lymphoplasmacytic cells overproducing only alpha heavy chains in the small intestinal mucosa. This disease occurs mainly in the Mediterranean region and low-income countries of the Middle East, and it is regarded as one of the rare malignancies in which antibiotics form the basis of treatment, since remission can be achieved with antibiotic therapy alone (tetracycline, ampicillin, metronidazole) at early stages. This observation, on a principle similar to H. pylori eradication in MALT lymphoma, supports the pathogenic theory that an infectious agent induces immunoproliferation through persistent antigenic stimulation.
The current WHO classification (5th edition, 2022) defines WM as the subtype making up most cases of lymphoplasmacytic lymphoma (LPL) and requires the MYD88 L265P mutation and bone marrow involvement as diagnostic criteria. Under ICD-10/KCD-8, C88 is subdivided into WM (C88.0), alpha heavy chain disease (C88.1), gamma heavy chain disease (C88.2), other heavy chain diseases (C88.3), immunoproliferative small intestinal disease (C88.7), other malignant immunoproliferative diseases (C88.8), and malignant immunoproliferative disease, unspecified (C88.9).
Summary: Family history, immune abnormalities, infections (Campylobacter, EBV, HCV), and genetic predisposition act in combination, and the MYD88 L265P somatic mutation acts as the key disease-triggering factor.
The causes of malignant immunoproliferative diseases are not singular; genetic predisposition, immune dysregulation, chronic antigenic stimulation, and environmental factors act in combination.
In first-degree relatives of WM patients, the risk of WM or IgM monoclonal gammopathy (IgM MGUS) is 5–20 times higher than in the general population. Familial WM studies have associated TNF gene polymorphisms, IL-6 promoter variants, and others with increased susceptibility, and recent genome-wide association studies (GWAS) have reported that single nucleotide polymorphisms (SNPs) in the 6p21 (HLA region), 14q32 (IGH region), and 2p23 regions are associated with WM risk.
The risk of WM is significantly increased in patients with autoimmune diseases (rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus), suggesting that chronic B-cell stimulation and impaired immune surveillance contribute to the emergence of malignant clones. IgM MGUS (monoclonal gammopathy of undetermined significance) is a precursor lesion that transforms into WM, with a transformation rate of about 1.5% per year. Regulatory T-cell (Treg) dysfunction and reduced NK-cell immune surveillance have also been reported as related factors.
In alpha heavy chain disease (IPSID), Campylobacter jejuni infection is known to induce a persistent IgA-type immune response in the small intestinal mucosa, selecting clones that overproduce only alpha heavy chains. Hepatitis C virus (HCV) infection has an established association with splenic marginal zone lymphoma (part of the C88 category), and EBV is detected in some cases of WM and heavy chain disease. Cases in which splenic marginal zone lymphoma reached remission with HCV antiviral therapy alone have been reported, showing that viral antigenic stimulation is a key driver of B-cell clonal proliferation.
There are epidemiological data indicating that agricultural work (pesticide exposure), occupational organic solvent exposure, and nuclear radiation exposure are associated with an increased risk of LPL/WM, but the strength of association is not strong. Smoking and obesity have also been reported as risk factors in some epidemiological studies.
IgM MGUS, the precursor lesion of WM, is defined as serum IgM <30 g/L, bone marrow involvement <10%, and no organ damage, and it progresses to WM or IgM-related disorders at a rate of about 1.5% per year. Factors suggested to increase the risk of progression include high IgM levels, abnormal immunoglobulin ratios (decreased IgA/IgG), and the presence of the MYD88 L265P variant.
Summary: MYD88 L265P (>90%) and CXCR4 mutations (about 40%) are the key genetic abnormalities of WM, and MYD88 mediates NF-κB activation through BTK, providing the basis for targeted therapy.
MYD88 (Myeloid differentiation primary response 88) is an adaptor protein in Toll-like receptor (TLR) and IL-1 receptor signaling. The L265P substitution mutation constitutively activates the MYD88 protein, promoting formation of signaling complexes with the IRAK1/IRAK4 kinases and BTK, ultimately persistently activating the NF-κB and PI3K/AKT pathways. This mutation is detected in 90–95% of WM/LPL patients and is markedly distinguished in frequency from multiple myeloma (rare), ABC-type DLBCL (about 30%), and CLL (rare), making it highly specific for the diagnosis of WM. It can be detected in bone marrow and serum cell-free DNA by allele-specific PCR or next-generation sequencing (NGS), and highly sensitive digital PCR (ddPCR) is used for minimal residual disease (MRD) monitoring.
CXCR4 (CXC chemokine receptor 4) is a chemokine receptor involved in bone marrow homing and survival of B cells. Somatic CXCR4 mutations (mainly S338X or other C-terminal truncating/frameshift mutations) are found in about 35–40% of WM patients. CXCR4 mutations enhance AKT and ERK signaling through the CXCL12/CXCR4 axis, promoting bone marrow retention and survival of tumor cells, and are clinically associated with delayed response to and resistance to ibrutinib treatment. CXCR4 wild-type WM tends to respond more rapidly to BTK inhibitors.
CD79B (B-cell receptor co-signaling subunit) mutations are found in about 15% of WM and likewise enhance BCR signaling and NF-κB. Among cytogenetic abnormalities, 6q deletion (6q21–23) is observed in about 40–50% and is associated with inactivation of BLIMP1 (located at 6q21) and PTPRK (6q22). In addition, 13q14 deletion (RB1, DLEU2 locus), 17p deletion (TP53), and 18q amplification are reported in some cases but are not specific to WM.
In alpha heavy chain disease, a deletion arises in IGH gene rearrangement between the variable region preceding the CH1 (Cα1) domain joined to the J segment and the C region, so that only incomplete alpha heavy chains incapable of secretion are produced. On molecular clonal analysis, this B-cell clone is of mucosa-associated lymphoid tissue (MALT) origin, and at early stages it is an antigen (Campylobacter)-dependent clone in which remission is possible after antibiotic treatment.
In gamma heavy chain disease, IGH somatic mutations accompanied by CH1 domain deletion produce gamma heavy chain fragments that cannot bind light chains. Accompanied by BCL2 overexpression and other lymphoma-related genetic abnormalities, it can appear in association with various underlying lymphomas such as multiple myeloma, marginal zone lymphoma, and DLBCL.
Summary: WM is a rare lymphoma with 1,500–2,000 cases per year in the United States and occurs rarely in Korea as well; the median age at onset is 70 years, and it is slightly more common in men.
WM is a rare disease accounting for about 1–2% of all non-Hodgkin lymphomas. In the United States, about 1,500–2,000 new cases occur annually, with an annual incidence of about 0.3–0.4 per 100,000 population. European data are similar, and the highest incidence is seen in North America and Europe. It occurs relatively rarely in Asia, especially East Asia (Korea, Japan, China), but systematic registry data are lacking.
In the Korea Central Cancer Registry data of the National Cancer Information Center (NCCI), WM is counted separately as C88.0 and is extremely rare at a few dozen cases per year. In Korean multicenter lymphoma studies, WM/LPL is reported to account for less than 1% of all B-cell lymphomas. Alpha heavy chain disease and other heavy chain diseases are rare even in the West, and epidemiological data in Korea are limited to case reports.
The median age at diagnosis of WM is about 70 years (range: 40–90 years), concentrated in older adults, and onset before age 40 is very rare. The male-to-female ratio is about 1.5:1, slightly more common in men. Racially, incidence is about 3 times higher in white than in Black individuals, reflecting differences in genetic background. IgM MGUS is about 20 times more common than WM and is found in about 0.5–0.6 per 100,000 population.
Alpha heavy chain disease (IPSID) occurs mainly in low-income countries of the Mediterranean region, the Middle East, Africa, and South Asia, and is concentrated in areas with poor sanitation where Campylobacter and other enteric infections are widespread. The age at onset is relatively young, and it also appears in people in their 10s to 30s. Gamma heavy chain disease and mu heavy chain disease are very rare worldwide, with only a few hundred cases of each reported in the literature.
Summary: MYD88 L265P → IRAK4/BTK complex → NF-κB and JAK/STAT3 activation is central, and CXCR4 mutations mediate bone marrow retention and BTK inhibitor resistance.
In normal B cells, TLR/IL-1 receptor stimulation induces a transient signal that activates the IRAK4→IRAK1→TRAF6→NF-κB pathway via MYD88. In WM, the MYD88 L265P mutation causes MYD88 to dimerize constitutively and form a stable signaling complex (myddosome) with IRAK4 and BTK, persistently activating the NF-κB (p50/p65) and PI3K/AKT pathways. As a result, expression of anti-apoptotic genes (BCL-XL, MCL-1, BCL2) increases, and secretion of proliferation-related cytokines such as MYC, IL-6, and CXCL13 is promoted. BTK inhibitors (ibrutinib, zanubrutinib) bind covalently to the C481 residue of BTK and block this signal, thereby inhibiting the proliferation and survival of WM cells. The second-generation BTK inhibitor zanubrutinib has high selectivity for BTK, reducing adverse effects (atrial fibrillation, bleeding, diarrhea) caused by inhibition of off-target kinases such as ITK, EGFR, and TEC.
CXCR4 mutations enhance AKT and ERK signaling in response to CXCL12 stimulation and delay receptor internalization, so that CXCR4 remains persistently expressed on the cell surface. This promotes homing and retention of tumor cells to bone marrow stromal cells and increases access to survival signals provided by the bone marrow microenvironment (IL-6, IGF-1, BAFF, CD40L). Clinically, CXCR4-mutated WM tends to respond more slowly to BTK inhibitors, have difficulty achieving deeper remissions, and have a shorter time to progression.
B-cell receptor (BCR) signaling also plays an important role in WM. CD79B mutations inhibit BCR internalization, increasing surface BCR expression and augmenting the SYK→BTK→NF-κB pathway. This further strengthens the rationale for BTK inhibitor treatment, and PI3K inhibitors (idelalisib, copanlisib) also show activity in WM by targeting downstream BCR pathways.
The WM clone overproduces monoclonal IgM; IgM has a pentameric structure with a large molecular weight (about 900 kDa) and markedly raises plasma viscosity. When serum IgM exceeds about 30–40 g/L, hyperviscosity syndrome develops due to increased plasma viscosity. IgM can also act as a cryoglobulin or bind to nerve myelin (myelin-associated glycoprotein, MAG, etc.), causing antibody-mediated peripheral neuropathy. In addition, IgM may bind to red blood cell surface antigens, causing autoimmune hemolytic anemia, or impair platelet function, causing a bleeding tendency.
When chronic infection such as Campylobacter persists in the small intestinal mucosa, reactive proliferation of IgA plasma cells occurs. In the process, CH1 domain deletion and clonal rearrangement occur in the IGH gene, and a clone emerges that secretes only alpha heavy chain fragments unable to bind light chains. Initially it is antigen-dependent and responds to antibiotic treatment, but with accumulation of additional genetic damage (chromosomal abnormalities, TP53 mutations, etc.) it gradually shifts to antigen-independent autonomous proliferation and takes on the clinical picture of progressive lymphoma.
Summary: The key symptoms of WM are anemia (fatigue, dyspnea), hyperviscosity syndrome (headache, decreased vision, confusion), IgM-related neuropathy, and B symptoms (fever, night sweats, weight loss).
About 40–50% of WM patients have normocytic, normochromic anemia due to bone marrow involvement and IgM-induced red cell aggregation (rouleaux formation). This presents as fatigue, exertional dyspnea, palpitations, pallor, and reduced concentration and is the symptom patients most commonly report. When autoimmune hemolytic anemia is present, jaundice and dark brown urine may occur. When associated with cryoglobulinemia, Raynaud phenomenon, cyanosis, and skin necrosis may occur on exposure to cold.
When serum IgM concentration rises sharply, plasma viscosity increases and hyperviscosity syndrome develops. Typical symptoms are headache, dizziness, tinnitus, hearing loss, decreased or blurred vision (funduscopic findings: sausage-shaped retinal veins, flame-shaped hemorrhages), and bleeding from the nasal and oral mucosa. In severe cases, decreased consciousness, stupor, and stroke-like neurological deficits may occur; this is a medical emergency requiring plasmapheresis. Hyperviscosity syndrome commonly occurs when IgM >40 g/L or serum viscosity >4 cP, but the individual symptomatic threshold is more important than the absolute IgM level.
Monoclonal IgM antibodies bind to MAG (myelin-associated glycoprotein), gangliosides (GM1, GD1b, etc.), sulfatide, and other components of the peripheral nerve myelin sheath, causing IgM-associated peripheral neuropathy. Clinically, a slowly progressive, sensory-predominant, distal symmetric polyneuropathy (demyelinating type, reduced conduction velocity on EMG) is characteristic. Sensory symptoms (numbness, burning, loss of vibration and position sense) predominate, and motor impairment is relatively mild. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) is associated with lambda light chain plasma cell disorders rather than WM but needs to be differentiated.
B symptoms, consisting of fever (unexplained, 38°C or higher), night sweats, and weight loss of more than 10% within 6 months, occur in about 15–20% of WM patients and are one indicator of the need for treatment. Generalized fatigue, anorexia, and chills commonly accompany them, and the appearance of B symptoms in patients under long-term observation (watch-and-wait) is a signal to start treatment.
When monoclonal IgM protein coats coagulation factors (especially factor VIII, vWF) and impairs their function, or binds to the platelet surface and causes platelet dysfunction, mucosal bleeding (epistaxis, gum bleeding, gastrointestinal bleeding) occurs. The nasal and gum bleeding originally described by Waldenström corresponds to this and is also related to vascular fragility in the hyperviscous state.
Chronic diarrhea, steatorrhea (malabsorption), abdominal pain, weight loss, and edema due to hypoproteinemia are characteristic. Malabsorption syndrome due to small intestinal mucosal involvement predominates, and in the late stage, intestinal obstruction, intestinal perforation, and intestinal bleeding may occur. Gamma heavy chain disease shows fever, lymphadenopathy, splenomegaly, and palatal edema (characteristic).
Summary: The key physical examination findings in WM are asymptomatic lymphadenopathy, splenomegaly, retinal venous changes (ophthalmoscopy), pallor, and peripheral nerve deficits.
Painless lymphadenopathy in the cervical, axillary, inguinal, and other regions is found in about 20–30% of WM patients. Splenomegaly is observed in about 10–20%, and hepatomegaly in 5–15%. When the spleen is enlarged on abdominal palpation, patients may report dull left upper quadrant pain and early satiety.
Funduscopic examination is essential for the diagnosis of WM and the assessment of hyperviscosity. Dilation and tortuosity of retinal veins (sausage/string-of-sausages appearance), flame-shaped hemorrhages, exudates, and papilledema may be observed. These findings directly reflect increased plasma viscosity and improve after treatment (plasmapheresis, antitumor therapy).
Patients with IgM-associated peripheral neuropathy show findings such as loss of distal proprioception, reduced vibration sense, a positive Romberg test, sensory ataxia, and absent Achilles tendon reflexes. Motor abnormalities are relatively mild, but in severe cases distal muscle weakness may be present.
When cryoglobulinemia is present, peripheral cyanosis, livedo reticularis, purpura, and skin necrosis may occur. Schnitzler syndrome (IgM monoclonal gammopathy + urticaria + fever + arthralgia) is an autoimmune skin syndrome that occurs in association with IgM MGUS or early WM.
An abdominal mass due to mesenteric lymphadenopathy may be felt on abdominal palpation. Edema due to nutritional deficiency (hypoalbuminemia), muscle weakness, and growth retardation (pediatric patients) are observed. Fingertip deformity (cyanosis) and hyperkeratotic skin changes rarely accompany it.
Summary: Serum protein electrophoresis (SPEP) and IgM quantification are the first-line screening tests; monoclonal IgM is confirmed by immunofixation electrophoresis, and serum viscosity is measured to assess the risk of hyperviscosity syndrome.
Serum protein electrophoresis (SPEP) is the most basic screening test for detecting a monoclonal protein, with an M-protein spike appearing in the beta to gamma region (characteristic of IgM). IgM concentration is measured by IgM quantification (immunonephelometry), and immunofixation electrophoresis (IFE) confirms monoclonality and the heavy chain (IgM) and light chain (κ or λ) type. Monoclonal IgM is characteristic of WM, while IgA or IgG monoclonal proteins suggest multiple myeloma or other plasma cell disorders rather than WM. In alpha heavy chain disease, a monoclonal peak is not distinct on SPEP, so alpha heavy chain fragments must be detected by special immunoelectrophoresis or urine immunoelectrophoresis.
Normal serum viscosity is 1.4–1.8 cP, and hyperviscosity symptoms may appear at 4 cP or higher. It must be measured when IgM >40 g/L or when there are hyperviscosity symptoms. It is used to decide on and monitor plasmapheresis.
Complete blood count (CBC) characteristically shows normochromic anemia, normal or decreased platelets, and normal white blood cells. The erythrocyte sedimentation rate (ESR) is markedly elevated (in proportion to IgM concentration). Rouleaux formation of red blood cells may be seen on the peripheral blood smear. Serum β2-microglobulin (β2-MG), LDH, and albumin are used for prognostic assessment. Cryoglobulin testing (blood must be drawn and kept at 37°C body temperature), the direct Coombs test (DAT), and complement (C3, C4) are also performed.
Renal function (BUN, Cr), liver function (LFT), electrolytes, uric acid, and LDH are evaluated. ECG and echocardiography are needed to assess baseline cardiac function before treatment and are especially important for assessing atrial fibrillation risk with ibrutinib treatment.
Summary: The diagnosis of WM is established by serum monoclonal IgM + ≥10% lymphoplasmacytic cell involvement on bone marrow biopsy + the MYD88 L265P mutation; this triad constitutes the diagnostic criteria.
The requirements for a diagnosis of WM under the current WHO 5th edition (2022) criteria are as follows: ① positive serum monoclonal IgM (regardless of concentration), ② histological confirmation of lymphoplasmacytic lymphoma (LPL) on bone marrow biopsy (mixed infiltration of small lymphocytes, plasma cells, and lymphoplasmacytic cells, typically in an intertrabecular pattern), ③ confirmation of IgM secretion. MYD88 L265P is highly specific for the diagnosis but is not an essential WHO criterion and is used as supporting evidence. MYD88 wild-type IgM LPL tends to be excluded from WM, and other diagnoses such as marginal zone lymphoma must be excluded.
Bone marrow trephine biopsy is essential for diagnosing WM and assessing the extent of bone marrow involvement. The histological finding is a mixed infiltration of small lymphocytes, lymphoplasmacytic cells, and plasma cells in an intertrabecular pattern, with a characteristic immunophenotype of CD20+, CD22+, CD79a+, sIgM+ and CD5-, CD10-, CD23-, CD103-, cyclin D1-. An increase in bone marrow mast cells is often present (CD117+, tryptase+). Flow cytometry confirms the immunophenotype of the lymphoplasmacytic clone and also quantifies the CD38+CD138+ plasma cell component.
MYD88 L265P is detected in bone marrow or peripheral blood mononuclear cells by allele-specific PCR (AS-PCR) or next-generation sequencing (NGS). Highly sensitive methods (ddPCR) are useful in early stages with low clonal burden or for assessing treatment response. CXCR4 mutation testing is performed before BTK inhibitor treatment and distinguishes C-terminal truncating mutations from frameshift mutations. Cytogenetics (FISH: 6q-, 13q-, TP53, MYC, etc.) and conventional karyotyping are also used for prognostic assessment and treatment planning.
Whole-body CT (chest-abdomen-pelvis) is used to assess the extent of lymphadenopathy and organomegaly. PET-CT is performed when Richter transformation to DLBCL is suspected rather than for simple WM. Brain MRI is performed when Bing-Neel syndrome (central nervous system involvement by WM) is suspected (cognitive decline, gait abnormality, cranial nerve palsy, etc.), and the diagnosis is confirmed by cerebrospinal fluid examination (identification of WM cells, detection of MYD88 L265P).
In patients with gastrointestinal symptoms and malabsorption, alpha heavy chain fragments are identified by serum or urine immunoelectrophoresis. Small bowel endoscopic biopsy (proximal jejunum) confirms lymphoplasmacytic infiltration and villous atrophy, and immunohistochemistry detects plasma cells positive for IgA heavy chain and negative for light chain. Molecular biologically, deletion of the CH1 domain of the IGH gene is confirmed.
| Test | Purpose | Notes |
|---|---|---|
| SPEP + IFE | Confirmation of monoclonal IgM | First-line screening |
| IgM quantification | Tumor burden indicator | Tracking treatment response |
| Serum viscosity | Assessment of hyperviscosity risk | ≥4 cP → risk of symptoms |
| Bone marrow biopsy + aspiration | Histological confirmation of LPL, quantification of involvement | Essential |
| MYD88 L265P (AS-PCR/NGS) | WM-specific mutation | Diagnostic specificity >90% |
| CXCR4 mutations | Predicting BTK inhibitor response | Recommended before treatment |
| Flow cytometry | Confirmation of immunophenotype | CD20+, CD5-, CD10- |
| PET-CT | When Richter transformation is suspected | Optional |
| Brain MRI + CSF | Bing-Neel syndrome | Performed with CNS symptoms |
Summary: For WM requiring treatment, BTK inhibitors (zanubrutinib, ibrutinib) or rituximab-based combination chemotherapy (DRC, BR) are used, and autologous transplantation is considered in transplant-ineligible or young patients.
In WM patients who are asymptomatic, have stable IgM, and have mild cytopenias, observation (watch-and-wait) is carried out without immediate treatment. Indications for treatment are one or more of the following: ① Hgb ≤10 g/dL, ② platelets <100×10⁹/L, ③ hyperviscosity syndrome, ④ symptomatic lymphadenopathy/organomegaly, ⑤ symptomatic IgM-related neuropathy, cryoglobulinemia, or autoimmune cytopenia, ⑥ B symptoms, ⑦ renal involvement. The median time until treatment is needed is 1–3 years or more, and some patients go for decades with observation alone.
Ibrutinib (420 mg once daily) was the first BTK inhibitor to receive FDA approval for WM in 2015, showing an overall response rate (ORR) of about 90%, a major response rate (MRR) of 70–75%, and a median progression-free survival (PFS) of about 4 years in relapsed/refractory WM. It shows similar efficacy in first-line treatment as well, but adverse effects such as atrial fibrillation (15–20%), bleeding (epistaxis, bruising), and gastrointestinal symptoms were problematic.
Zanubrutinib (160 mg twice daily or 320 mg once daily), compared with ibrutinib in the phase 3 ASPEN trial (N Engl J Med 2020), had a significantly higher combined rate of complete response (CR) + very good partial response (VGPR) (28% vs 19%, p=0.0261) and markedly lower rates of atrial fibrillation (2% vs 15%) and major bleeding. Accordingly, zanubrutinib has been approved in several countries, including Korea, for first-line and relapsed/refractory treatment of WM, and many guidelines prefer it over ibrutinib. Because relapse rates are high when BTK inhibitor treatment is stopped after achieving a response, continuous administration is the principle.
In transplant-eligible patients or those in whom BTK inhibitor use is limited by cardiovascular disease, DRC (Dexamethasone + Rituximab + Cyclophosphamide) or BR (Bendamustine + Rituximab) is used as standard therapy. DRC (6 cycles) is reported to have an ORR of 83% and a median PFS of about 35 months. BR has excellent efficacy with an ORR above 90% and a median PFS of about 69 months (first-line treatment of WM), but myelotoxicity and immunosuppression are problems. With rituximab monotherapy, an IgM flare, in which IgM transiently surges, can occur; therefore, when baseline IgM is high or there is a risk of hyperviscosity, it is recommended to perform plasmapheresis before rituximab administration or to split the rituximab dose (step-up).
In the INNOVATE trial (iNNOVATE study, phase 3), the ibrutinib + rituximab combination markedly improved PFS compared with rituximab alone (30-month PFS 82% vs 28%). In MYD88 wild-type WM patients as well, ibrutinib + rituximab showed better results than ibrutinib alone, so combination therapy is preferred in MYD88 wild-type patients.
When hyperviscosity syndrome occurs, plasmapheresis is an emergency measure that immediately removes IgM and rapidly improves symptoms. A single plasmapheresis can remove 40–60% of serum IgM, and it is generally performed 1–3 times until symptoms improve. Because plasmapheresis is a temporary measure, antitumor therapy must always be given concurrently.
Even in the BTK inhibitor era, ASCT is considered as consolidation after intensified treatment in young patients (under 65) with relapsed/refractory WM or an aggressive course. However, given that WM is a slowly progressive disease and the advanced median age at onset, the number of patients eligible for ASCT is limited. Allogeneic transplantation (allo-SCT) offers the possibility of cure in young patients with repeated relapse/refractoriness, but transplant-related morbidity and mortality are high.
In WM patients resistant or intolerant to BTK inhibitors, venetoclax shows activity as a BCL2 inhibitor. Small clinical studies have reported an ORR of about 75–80% and a median PFS of about 30 months. Ibrutinib + venetoclax combination (aiming for MRD negativity) is also under investigation. Noncovalent BTK inhibitors such as pirtobrutinib are being developed to overcome the C481S resistance mutation, and early clinical trials are also under way in WM.
In central nervous system involvement by WM (Bing-Neel syndrome), ibrutinib, which crosses the blood-brain barrier (CNS penetration confirmed), has shown efficacy. High-dose methotrexate, cytarabine (ara-C), and the combination of the two are also used, and radiation therapy can be applied to focal lesions.
Stage A (confined to the mucosa): antibiotic therapy such as tetracycline, ampicillin, and metronidazole for 6 months. Complete remission rate about 30–70%. Stages B and C (submucosal involvement or beyond): antibiotics are combined with CHOP-type or CHOP-R chemotherapy. For localized lesions amenable to complete resection, chemotherapy after surgery is considered.
Summary: WM is a chronic hematologic cancer that is treatable but rarely cured with current methods; median survival is about 8–10 years, and the 5-year survival rate ranges from 36% to 87% depending on the IPSSWM risk group.
The International Prognostic Scoring System for WM (IPSSWM) scores the following five adverse prognostic factors at 1 point each: ① age >65 years, ② Hgb ≤11.5 g/dL, ③ platelets ≤100×10⁹/L, ④ β2-microglobulin >3 mg/L, ⑤ IgM >70 g/L. Low risk (0–1 point, age ≤65 years): 5-year OS 87%; intermediate risk (2 points or age >65 years only): 5-year OS 68%; high risk (3 or more points): 5-year OS 36%. Overall survival outcomes have improved since the introduction of BTK inhibitors, but further improvement is needed in the high-risk group.
Carrying MYD88 L265P is specific for the diagnosis of WM but has limited prognostic value on its own. CXCR4 mutations are associated with delayed response to BTK inhibitor treatment and shorter PFS. TP53 variants (17p deletion) are associated with an aggressive course and indicate a particularly poor prognosis in treatment resistance. MYD88 wild-type WM generally has a poorer prognosis than WM carrying MYD88 L265P and requires differentiation from other diagnoses (marginal zone lymphoma, plasma cell myeloma, etc.).
Histological transformation of WM to aggressive large B-cell lymphoma occurs in 1–2% over about 3–10 years of follow-up and is diagnosed by biopsy of sites with increased FDG uptake on PET-CT. The prognosis after transformation is very poor, with a median survival of only a few months. Central nervous system relapse (Bing-Neel syndrome) is also not uncommon, and an active CNS prophylaxis strategy is needed.
Long-term survival is possible when complete remission is achieved with antibiotic therapy at an early stage (stage A). However, when the disease has progressed to stage B or C, the response rate to chemotherapy is low and the 5-year survival rate is poor at under 30%. The prognosis of gamma heavy chain disease varies greatly with the type and activity of the underlying lymphoma, and some cases remain stable for decades.
Summary: There is no primary prevention for WM, but regular follow-up of IgM MGUS patients (annual IgM and blood counts) and management of risk factors (HCV infection, pesticide exposure) are key to secondary prevention.
There is currently no specific means of primary prevention for WM and malignant immunoproliferative diseases. Hepatitis C virus (HCV) infection, a known epidemiological risk factor, can be treated with direct-acting antivirals (DAAs) to lower the risk of HCV-associated lymphoproliferative disorders. For alpha heavy chain disease (IPSID), improved sanitation and prevention of chronic intestinal infection may theoretically contribute to preventing disease onset.
Patients with IgM MGUS, a precursor lesion of WM, show a progression rate of 1.5% per year and therefore require regular follow-up. Follow-up schedule: serum IgM, complete blood count, and protein electrophoresis are repeated 6 months after diagnosis, and if stable, follow-up is annual thereafter. When serum IgM rises sharply, anemia worsens, or B symptoms appear, additional tests (bone marrow biopsy, MYD88 mutation testing) are performed early. Prophylactic treatment is not currently recommended.
WM patients are susceptible to bacterial infections due to hypogammaglobulinemia (decreased normal IgG and IgA). With recurrent infections, intravenous immunoglobulin (IVIG) replacement therapy is considered. During BTK inhibitor treatment, prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia (PCP) and with acyclovir or valacyclovir for herpes zoster is considered. Influenza vaccine (annually), pneumococcal vaccine, and COVID-19 vaccine (mRNA recommended) are given, keeping in mind the reduced immune response after rituximab treatment.
To minimize the risk of atrial fibrillation during BTK inhibitor (especially ibrutinib) treatment, baseline cardiac function is assessed with ECG and echocardiography before treatment, and blood pressure control and electrolyte management are carried out thoroughly. To prevent bleeding, caution is used with concomitant anticoagulants or aspirin, and interruption of the BTK inhibitor for 5–7 days before procedures is considered. To prevent hyperviscosity syndrome, treatment is started early when IgM is trending upward, and the risk of IgM flare is assessed in advance before rituximab monotherapy.
WM is a chronic disease requiring long-term treatment and follow-up. When peripheral neuropathy is present, function is maintained with physical therapy, occupational therapy, and assistive devices. Patients with cryoglobulinemia should keep warm and avoid exposure to cold environments. Mental health support (counseling, support groups) and a cancer survivorship care plan are established to improve the patient's overall quality of life.